BBB Kit™ References（April 10, 2020）

MBT-24H (12 publications)

Permeability Assay (9 publications)

Yamaguchi S et al., Novelcyclicpeptidesfacilitatingtranscellularblood-brainbarriertransport of macromolecules in vitro and in vivo. Journal of Controlled Release. 2020 doi:10.1016/j.jconrel.2020.03.001

Shimizu Yu et al. Neuroprotective Effects of Endogenous Secretory Receptor for Advanced Glycation End-products in Brain Ischemia. Aging Dis 2019 http://www.aginganddisease.org/EN/10.14336/AD.2019.0715

Amano M et al. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications. Antimicrob Agents Chemother,2019 https://doi.org/10.1128/AAC.00466-19

Yamamoto Y et al. Vascular RAGE transports oxytocin into the brain to elicit its maternal bonding behaviour in mice. Communications Biologyvolume 2, Article number: 76 (2019) https://doi.org/10.1038/s42003-019-0325-6

Lazzarini C et al. Acylhydrazones as antifungal agents targeting the synthesis of fungal sphingolipids. Antimicrob Agents Chemother. 2018 Mar 5. doi: 10.1128/AAC.00156-18.

Yamashita S et al. Mechanisms of carnosine-induced activation of neuronal cells. Biosci Biotechnol Biochem. 2017 Dec 11:1-6.

Amano M et al. A modified P1 moiety enhances in vitro antiviral activity against various multidrug-resistant HIV-1 variants and in vitro central nervous system penetration properties of a novel nonpeptidic protease inhibitor, GRL-10413. Antimicrob Agents Chemother. 2016;60(12):7046–59.

Amano M et al. A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro. Antimicrob Agents Chemother. 2015;59(5):2625–35.

Gómez PMS et al. GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration. Antimicrob Agents Chemother. 2013;57(12):6110–21.

BBB Analysis (3 publications)

Hashimoto Y et al. Claudin-5-binders enhance permeation of solutes across the blood-brain barrier in a mammalian model. J Pharmacol Exp Ther. 2017;363(2):275-283.

Yuka Torii et al. Metabolome analysis reveals the association between the kynurenine pathway and human herpesvirus 6 encephalopathy in immunocompetent children. Metabolomics (2017) 13: 126.

Tominaga N et al. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood–brain barrier. Nat Commun. 2015;6:6716

RBT-24H (22 publications)

Permeability Assay (16 publications)

Yamaguchi S et al., Novelcyclicpeptidesfacilitatingtranscellularblood-brainbarriertransport of macromolecules in vitro and in vivo. Journal of Controlled Release. 2020 doi:10.1016/j.jconrel.2020.03.001

Accelerative effects of carbazole-type alkaloids from Murraya koenigii on neurite outgrowth and their derivative's in vivo study for spatial memory. Yano, M., Nakashima, S., Kasa, S. et al.
J Nat Med (2020). https://doi.org/10.1007/s11418-020-01388-8

Yano, M. et al. BBB-permeable aporphine-type alkaloids in Nelumbo nucifera flowers with accelerative effects on neurite outgrowth in PC-12 cells. J Nat Med (2019). https://doi.org/10.1007/s11418-019-01368-7

Kimiyuki S et., al. Brain Targeting of Acyl-CoA:Cholesterol O-Acyltransferase-1 Inhibitor K-604 via the Intranasal Route Using a Hydroxycarboxylic Acid Solution. ACS Omega 2019,4,16,16943-16955 DOI: 10.1021/acsomega.9b02307

Hase T et al. Rosmarinic acid suppresses Alzheimer's disease development by reducing amyloid β aggregation by increasing monoamine secretion. Sci Rep. 2019 Jun 18;9(1):8711. doi: 10.1038/s41598-019-45168-1.

Daisuke I et al. Type I interferon protects neurons from prions in in vivo models. Brain, awz016, https://doi.org/10.1093/brain/awz016

Unno K et al. Blood-Brain Barrier Permeability of Green Tea Catechin Metabolites and their Neuritogenic Activity in Human Neuroblastoma SH-SY5Y Cells. Mol Nutr Food Res. 2017;61(12).doi: 10.1002/mnfr.201700294

Jung Seok Kim, Dae Hwan Shin, Jin-Seok Kim. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells. J Control Release. 2017;269:245-257.

Yoshimaru T et al. Stapled BIG3 helical peptide ERAP potentiates anti-tumour activity for breast cancer therapeutics. Scientific Reports 2017;7(1):1821.

Kurokawa Y et al. Aggregation is a critical cause of poor transfer into the brain tissue of intravenously administered cationic PAMAM dendrimer nanoparticles. Int J Nanomedicine. 2017 May 24;12:3967-3975.

Watanabe Y et al. Design and synthesis of novel δ opioid receptor agonists with an azatricyclodecane skeleton for improving blood-brain barrier penetration. Bioorg Med Chem Lett. 2017 May 26. pii: S0960-894X(17)30571-1.

Pervin M et al. Blood brain barrier permeability of (−)-epigallocatechin gallate, its proliferation-enhancing activity of human neuroblastoma SH-SY5Y cells, and its preventive effect on age-related cognitive dysfunction in mice. Biochem Biophys Reports [Internet]. 2017;9(January):180–6.

Pelisch N et al. Plasminogen activator inhibitor-1 antagonist TM5484 attenuates demyelination and axonal degeneration in a mice model of multiple sclerosis. PLoS One. 2015;10(4):1–17.

Bohara M et al. C-type natriuretic peptide modulates permeability of the blood-brain barrier. J Cereb Blood Flow Metab. 2014;34(4):589–96.

Hanada S et al. Cell-based in vitro blood-brain barrier model can rapidly evaluate nanoparticles' brain permeability in association with particle size and surface modification. Int J Mol Sci. 2014;15(2):1812–25.

Spencer B et al. A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis. J Biol Chem. 2014;289(25):17917–31.

BBB Analysis (6 publications)

Wang Z et al., FTY720 Protects Against Ischemia–Reperfusion Injury by Preventing the Redistribution of Tight Junction Proteins and Decreases Inflammation in the Subacute Phase in an Experimental Stroke Model. Transl Stroke Res. 2020 https://doi.org/10.1007/s12975-020-00789-x

Shigemoto-Mogami Y, Hoshikawa K and Sato K. Activated Microglia Disrupt the Blood-Brain Barrier and Induce Chemokines and Cytokines in a Rat in vitro Model. Front. Cell. Neurosci., 13 December 2018 https://doi.org/10.3389/fncel.2018.00494

Zeniya S et al. Angubindin-1 opens the blood–brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system. J Control Release. 2018 May 10. doi: 10.1016/j.jconrel.2018.05.010.

Miyazaki W, Fujiwara Y, Katoh T. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the development and function of the blood-brain barrier. Neurotoxicology. 2016 Jan;52:64-71. doi: 10.1016/j.neuro.2015.11.003.

Takagi T et al. Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood–brain barrier. J Cereb Blood Flow Metab. 2015;0271678X15621499.

Muramatsu R et al. Prostacyclin prevents pericyte loss and demyelination induced by lysophosphatidylcholine in the central nervous system. J Biol Chem. 2015;290(18):11515–25.

RBC-12 (3 publications)

BBB Analysis

Xu L et al. Silver nanoparticles induce tight junction disruption and astrocyte neurotoxicity in a rat blood-brain barrier primary triple coculture model. Int J Nanomedicine. 2015;10:6105–19.

Permeability Assay (2 publications)

Tabuchi M et al. The blood-brain barrier permeability of 18b-glycyrrhetinic acid, a major metabolite of glycyrrhizin in glycyrrhiza root, a constituent of the traditional Japanese medicine yokukansan. Cell Mol Neurobiol. 2012;32(7):1139–46.

Imamura S et al. The blood-brain barrier permeability of geissoschizine methyl ether in Uncaria hook, a galenical constituent of the traditional Japanese medicine yokukansan. Cell Mol Neurobiol. 2011;31(5):787–93.

RBE-12 (5 publications)

Permeability Assay

Ohshima M. et al. Prediction of Drug Permeability Using In Vitro Blood–Brain Barrier Models with Human Induced Pluripotent Stem Cell-Derived Brain Microvascular Endothelial Cells. BioResearch.Nov. 2019. http://doi.org/10.1089/biores.2019.0026

Nishigaki R et al. Monosodium glutamate ingestion during the development period reduces aggression mediated by the vagus nerve in a rat model of attention deficit-hyperactivity disorder. Brain Res. 2018 Apr 9. pii: S0006-8993(18)30186-0. doi: 10.1016/j.brainres.2018.04.006.

BBB Analysis (3 publications)

Masago K et al. Lysophosphatidic acid receptor, LPA6, regulates endothelial blood-brain barrier function: Implication for hepatic encephalopathy. Biochem Biophys Res Commun. 2018 Jul 2;501(4):1048-1054. doi: 10.1016/j.bbrc.2018.05.106.

Zhang J et al. Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke. 2011;42(5):1420–8.

Lukic-Panin V et al. Free radical scavenger edaravone administration protects against tissue plasminogen activator induced oxidative stress and blood brain barrier damage. Curr Neurovasc Res [Internet]. 2010;7(4):319–29.

BMEC coating solution (4 publications)

Aoki H et al., Laminin 221 fragment is suitable for the differentiation of human induced pluripotent stem cells into brain microvascular endothelial-like cells with robust barrier integrity. Fluids Barriers CNS 17, 25 (2020). https://doi.org/10.1186/s12987-020-00186-4

Yamaguchi T et al., Effect of heat stress on blood-brain barrier integrity in iPS cell-derived microvascular endothelial cell models. PLoS One. 2019; 14(9): e0222113. doi: 10.1371/journal.pone.0222113

Kurosawa T. et al., Expression and Functional Characterization of Drug Transporters in Brain Microvascular Endothelial Cells Derived from Human Induced Pluripotent Stem Cells. Mol Pharm. 2018 Dec 3;15(12):5546-5555. doi: 10.1021/acs.molpharmaceut.8b00697

Kokubu Y, Yamaguchi T, Kawabata K. In vitro model of cerebral ischemia by using brain microvascular endothelial cells derived from human induced pluripotent stem cells. Biochem Biophys Res Commun. 2017 Apr 29;486(2):577-583. doi: 10.1016/j.bbrc.2017.03.092.